Frank Misselwitz

Title: Frank Misselwitz: Innovator in Thromboembolic Disorder Treatment

Introduction

Frank Misselwitz is a notable inventor based in Heidelberg, Germany. He has made significant contributions to the field of blood coagulation, particularly in the prevention and treatment of thromboembolic disorders. His innovative approach has the potential to improve patient outcomes in this critical area of healthcare.

Latest Patents

Frank Misselwitz holds a patent related to the prevention and treatment of thromboembolic disorders. The patent describes a method of treating such disorders by administering a direct factor Xa inhibitor in oral dosage form to patients. This method involves a once-daily administration, which is particularly beneficial for patients in need of effective treatment. The factor Xa inhibitor is characterized by a plasma concentration half-life indicative of a bid or tid administration interval, specifically 10 hours or less.

Career Highlights

Frank is associated with Bayer Intellectual Property GmbH, where he continues to work on innovative solutions in the medical field. His expertise in blood coagulation has positioned him as a key figure in the development of new therapeutic methods.

Collaborations

Frank has collaborated with notable colleagues, including Dagmar Kubitza and Son-Mi Park. Their combined efforts contribute to advancing research and development in thromboembolic disorder treatments.

Conclusion

Frank Misselwitz is a distinguished inventor whose work in thromboembolic disorder treatment exemplifies innovation in the medical field. His contributions are paving the way for improved therapeutic options for patients.